Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) ...
A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth forecasts in maintaining positive views ...
GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback